Personalized Nutrition for Diabetes Type 2

NCT ID: NCT03662217

Last Updated: 2019-02-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-10-28

Study Completion Date

2020-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will investigate the effect of personalized diet on blood glucose control in individuals with diabetes as compared with ADA diet.

The primary objective is to test whether personalized diets based on DayTwo's algorithm can improve glycemic control and metabolic health compared to standard ADA acceptable dietary approach for diabetes at the end of a 3-month intervention period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The prevalence of diabetes type 2 estimated to 628 Million people in the world by 2045 and was announced by the International Diabetes Federation (IDF) as one of the biggest epidemics in the history. Complications of diabetics Type 2 can range from high blood sugar include heart disease, strokes, diabetic retinopathy which can result in blindness, kidney failure, and poor blood flow in the limbs which may lead to amputations. It is also linked to other manifestations, collectively termed the metabolic syndrome, including obesity, hypertension, non-alcoholic fatty liver disease, hypertriglyceridemia and cardiovascular disease .

As blood glucose levels are mainly affected by food consumption, the growing number of blood glucose abnormalities is likely attributable to nutrition. Indeed, dietary and lifestyle changes normalize blood glucose levels in 55% -80% of the cases. Therefore, maintaining normal blood glucose levels is critical for preventing diabetes and its metabolic complications.

Currently, there are no effective methods for predicting the postprandial glycemic response (PPGR) of people to food. The current practice of using the meal carbohydrate content is a poor predictor of the PPGR and has limited efficacy. The glycemic index (GI), which quantifies PPGR to consumption of a single tested food type, and the derived glycemic load have limited applicability in assessing the PPGR to real-life meals consisting of arbitrary food combinations and varying quantities, consumed at different times of the day, and at different proximity to physical activity and other meals. Indeed, studies examining the effect of diets with a low glycemic index on TIIDM risk, weight loss, and cardiovascular risk factors yielded mixed results . The limited success of GI measure is probably due to the fact that it is a general index, which does not take into consideration the large variation between individuals in their glycemic response to food. It can be concluded, therefore, that in order to control glycemic response of an individual, we should build a personally tailored diet which takes into account various factors.

Although genetic factors influence the levels of fasting blood glucose and glycemic response to food, these factors only explain approximately 10% of the variance in the population. Supporting this claim is the fact that the number of people with diabetes is increasing in recent years regardless of patients' genetic background. In contrast, environmental factors such as the composition of the intestinal bacteria and their metabolic activity may affect the glycemic response. The entire bacteria population in the digestive tract (microbiome) consist of \~1,000 species with a genetic repertoire of \~3 million different genes. The microbiome is directly affected by our diet and directly affect the body's response to food. This special relationship between the host and the intestinal flora is reflected by the composition of bacteria unique to type 2 diabetes and in the significant changes in the bacteria composition upon transition from a diet rich in fiber to a "Western" diet rich in simple sugars.

Recently, DayTwo developed a highly accurate algorithm for predicting the personalized glucose response to food for each person based on the PNP Study conducted by the Weizmann Institute. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria. In a small-scale pilot study that was conducted by the Weizmann Institute using the algorithm, the researchers personally tailored dietary interventions to healthy and prediabetic people, which resulted in significantly improved PPGRs accompanied by consistent alterations to the gut microbiota. These findings led to hypothesize that tailoring personalized diets based on PPGRs predictions may achieve better outcomes in terms of controlling blood glucose levels and its metabolic consequences relative to the current standard nutritional therapy for diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Algorithm-based diet

Subjects randomized to this arm will receive personally tailored dietary recommendations based on their predicted glycemic responses according to the study algorithm.

Group Type EXPERIMENTAL

Algorithm-based diet

Intervention Type OTHER

Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria

ADA- based diet

Subjects randomized to this arm will receive nutritional recommendations according to the standard American dietary approach for treating diabetes

Group Type OTHER

ADA- based diet

Intervention Type OTHER

The American standard of care dietary guidelines for diabetes.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Algorithm-based diet

Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria

Intervention Type OTHER

ADA- based diet

The American standard of care dietary guidelines for diabetes.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetes Type 2 for at least 1 year (diagnosed by ADA criteria) and up to 20 years
* 7.5 \<= HbA1C \<= 9.5
* Stable dose of meds for 3 months
* Stable diet and lifestyle for 3 months
* Age -between 18 to 85
* BMI - between 25 to 35
* Capable of working with smartphone application
* At least 5 days of the food logging in screening week:

* At least 60% reported Kcals out of the recommended daily consumption
* At least 2 reported meals a day

Exclusion Criteria

* Short-acting insulin treatment
* Bariatric surgery
* Antibiotics/antifungal treatment in the last 3 months
* Use of weight-loss medication for less than 6 months
* Use of GLP-1 and SGLT-2 for less than 6 months
* People under another diet regime that is different from the ADA recommended diet
* Pregnancy or 3 months after giving birth, fertility treatments
* Chronic disease (e.g. HIV, Cushing syndrome, CKD, acromegaly, active hyperthyroidism etc.)
* Cancer and anticancer treatment in the last 5 years
* Psychiatric disorders (that in the eyes of the investigator should exclude the participant)
* Life-threatening food allergy
* Have received DayTwo nutrition recommendations in the past
* have been continuously using CGM\\FGM
* Any disorder, which in the investigator's opinion might jeopardize subject's safety or compliance with the protocol
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

DayTwo

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Davidi Bachrach

Role: STUDY_DIRECTOR

DayTwo COO

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Edith Wolfson Medical Center

Holon, , Israel

Site Status RECRUITING

Diabetes Medical Center

Tel Aviv, , Israel

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rony Bikovsky

Role: CONTACT

+972542299300

Tal Ofek, Ph.d

Role: CONTACT

+972505658786

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Tali Ganz

Role: primary

+972523374030

Vered Sason

Role: primary

+97236900333

References

Explore related publications, articles, or registry entries linked to this study.

Zeevi D, Korem T, Zmora N, Israeli D, Rothschild D, Weinberger A, Ben-Yacov O, Lador D, Avnit-Sagi T, Lotan-Pompan M, Suez J, Mahdi JA, Matot E, Malka G, Kosower N, Rein M, Zilberman-Schapira G, Dohnalova L, Pevsner-Fischer M, Bikovsky R, Halpern Z, Elinav E, Segal E. Personalized Nutrition by Prediction of Glycemic Responses. Cell. 2015 Nov 19;163(5):1079-1094. doi: 10.1016/j.cell.2015.11.001.

Reference Type RESULT
PMID: 26590418 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

003577

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Precision Diets for Diabetes Prevention
NCT03919877 ACTIVE_NOT_RECRUITING NA
The Breakfast Study
NCT05986097 COMPLETED PHASE1/PHASE2
Type 2 Diabetes Haptoglobin Phenotype and Vitamin E
NCT01113671 COMPLETED PHASE2/PHASE3